Key result
Elevated Lp(a) confers independent cardiovascular risk, but Middle Eastern population data remains scarce.
Answers are grounded in this paper and cite their sources.
This review highlights the critical gap in data regarding lipoprotein(a) genetics and its cardiovascular implications specifically within Middle Eastern populations.
Dyslipidemia, a significant risk factor for cardiovascular diseases (CVDs), is prevalent in the Middle East (ME) countries. With a variable prevalence, elevated lipoprotein (a) [Lp(a)] is the most widespread monogenic dyslipidemic disorder. Genetic studies have established Lp(a) as a heritable and independent risk factor for CVD. This discovery has shifted the perception of Lp(a) and the LPA gene from mere biomarkers of atherosclerotic risk to a viable target for therapeutic intervention. Significant differences in serum Lp(a) levels have been observed across racial and ethnic groups, with few independent genetic variants affecting Lp(a) levels outside the LPA gene region. Data specific to the ME and Arab populations remains scarce. ME populations exhibit genetic diversity and higher consanguinity rates, which may uniquely influence Lp(a) distribution and associated variations. This review examines the genetic and observational factors that shape Lp(a) levels and their role in CVD risk, focusing on ME populations.
No takes yet. Share an insight, caveat, or question.
El‐Menyar et al. (2025) conducted a review in Cardiovascular diseases. Elevated lipoprotein(a) was evaluated. Elevated lipoprotein(a) is a heritable and independent risk factor for cardiovascular disease, though data specific to Middle Eastern populations remains scarce.
Synapse has enriched 10 related papers. Consider them for comparative context: